Subchronic toxicity and immunotoxicity of MeO-PEG-poly(D,L-lactic-co- glycolic acid)-PEG-OMe triblock copolymer nanoparticles delivered intravenously into rats

Nanotechnology

Volumn 25, Issue 24, 2014, Pages

  Liao, Longfei ^a   Zhang, Mengtian ^a   Liu, Huan ^a   Zhang, Xuanmiao ^a   Xie, Zhaolu ^a   Zhang, Zhirong ^a   Gong, Tao ^a   Sun, Xun ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

in vivo toxicity; nanotoxicity; PEG PLGA PEG; safety evaluation

Indexed keywords

BLOOD; COPOLYMERS; DRUG DELIVERY; LYMPHOCYTES; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; RATS; TOXICITY;

CLINICAL OBSERVATION; DRUG DELIVERY SYSTEM; IN-VIVO; INTRAVENOUS ADMINISTRATION; NANOTOXICITY; PEG-PLGA-PEG; POLY(D , L-LACTIC-CO-GLYCOLIC ACID); SAFETY EVALUATIONS;

NANOPARTICLES;

DRUG CARRIER; MACROGOL DERIVATIVE; METHYLPOLY(ETHYLENE GLYCOL)-OLY(LACTIC ACID-CO-GLYCOLIC ACID)-POLY(ETHYLENE GLYCOL); NANOPARTICLE; POLYESTER;

ANIMAL; BODY WEIGHT; CHEMISTRY; CYTOLOGY; CYTOTOXICITY TEST; DOSE RESPONSE; DRUG EFFECTS; EATING; INTRAVENOUS DRUG ADMINISTRATION; MALE; PARTICLE SIZE; RAT; SPLEEN; SYNTHESIS; TISSUE SURVIVAL; WISTAR RAT;

ADMINISTRATION, INTRAVENOUS; ANIMALS; BODY WEIGHT; CYTOTOXICITY TESTS, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; EATING; MALE; NANOPARTICLES; PARTICLE SIZE; POLYESTERS; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; SPLEEN; TISSUE SURVIVAL;

EID: 84901659683     PISSN: 09574484     EISSN: 13616528     Source Type: Journal    
DOI: 10.1088/0957-4484/25/24/245705     Document Type: Article

References (43)

1. Colvin V L 2003 The potential environmental impact of engineered nanomaterials Nat. Biotechnol. 21 1166-70 (Pubitemid 37203347)
2. Oberdorster G 2010 Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology J. Intern. Med. 267 89-105
3. Hauck T S, Anderson R E, Fischer H C, Newbigging S and Chan W C 2010 In vivo quantum-dot toxicity assessment Small 6 138-44
4. Kasturirangan V et al 2013 In vivo toxicity evaluation of gold-dendrimer composite nanodevices with different surface charges Nanotoxicology 7 441-51
5. Fischer H C and Chan W C 2007 Nanotoxicity: the growing need for in vivo study Curr. Opin. Biotechnol. 18 565-71
6. Athanasiou K A, Niederauer G G and Agrawal C 1996 Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers Biomaterials 17 93-102 (Pubitemid 26031365)
7. Lü J-M, Wang X, Marin-Muller C, Wang H, Lin P H, Yao Q and Chen C 2009 Current advances in research and clinical applications of PLGA-based nanotechnology Expert Rev. Mol. Diagn. 9 325-41
8. Semete B, Booysen L, Lemmer Y, Kalombo L, Katata L, Verschoor J and Swai H S 2010 In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems Nanomed. 6 662-71
9. Parveen S and Sahoo S K 2011 Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery Eur. J. Pharmacol. 670 372-83
10. Duan Y, Nie Y, Gong T, Wang Q and Zhang Z 2006 Evaluation of blood compatibility of MeO-PEG J. Appl. Polym. Sci. 100 1019-23
11. Chang C W, Choi D, Kim W J, Yockman J W, Christensen L V, Kim Y H and Kim S W 2007 Non-ionic amphiphilic biodegradable PEG-PLGA-PEG copolymer enhances gene delivery efficiency in rat skeletal muscle J. Control. Release 118 245-53 (Pubitemid 46331900)
12. Jeong B, Bae Y H and Kim S W 2000 Drug release from biodegradable injectable thermosensitive hydrogel of PEG-PLGA-PEG triblock copolymers J. Control. Release 63 155-63 (Pubitemid 30046951)
13. He L, Yang L, Zhang Z R, Gong T, Deng L, Gu Z and Sun X 2009 In vitro evaluation of the genotoxicity of a family of novel MeO-PEG-poly(D,L-lactic-co- glycolic acid)-PEG-OMe triblock copolymer and PLGA nanoparticles Nanotechnology 20 455102
14. Semete B, Booysen L I, Kalombo L, Venter J D, Katata L, Ramalapa B, Verschoor J A and Swai H 2010 In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles Toxicol. Appl. Pharmacol. 249 158-65
15. Medzhitov R, Schneider D S and Soares M P 2012 Disease tolerance as a defense strategy Science 335 936-41
16. Dobrovolskaia M A, Aggarwal P, Hall J B and McNeil S E 2008 Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution Mol. Pharm. 5 487-95
17. Nel A, Xia T, Madler L and Li N 2006 Toxic potential of materials at the nanolevel Science 311 622-7 (Pubitemid 43191298)
18. Maynard A D, Warheit D B and Philbert M A 2011 The new toxicology of sophisticated materials: nanotoxicology and beyond Toxicol. Sci. 120 S109-29
19. Prabhu B M, Ali S F, Murdock R C, Hussain S M and Srivatsan M 2010 Copper nanoparticles exert size and concentration dependent toxicity on somatosensory neurons of rat Nanotoxicology 4 150-60
20. Schleh C, Semmler-Behnke M, Lipka J, Wenk A, Hirn S, Schaffler M, Schmid G, Simon U and Kreyling W G 2012 Size and surface charge of gold nanoparticles determine absorption across intestinal barriers and accumulation in secondary target organs after oral administration Nanotoxicology 6 36-46
21. Sun X, Duan Y-R, He Q, Lu J and Zhang Z-R 2005 PELGE nanoparticles as new carriers for the delivery of plasmid DNA Chem. Pharm. Bull. 53 599-603 (Pubitemid 40880246)
22. Wang C Y, Zhang Z, Duan Y R and Huang Y 2004 Preparation of nano-HAP as vectors for targeting delivery system Key Eng. Mater. 254 887-90
23. Gad S C, Sharp K L, Montgomery C, Payne J D and Goodrich G P 2012 Evaluation of the toxicity of intravenous delivery of auroshell particles (gold-silica nanoshells) Int. J. Toxicol. 31 584-94
24. Gao J, Ding X, Chu C, Lu L, Zhang Y, Chen Y, Fan W, Li G and Gao S 2009 Dry powder inhalations containing thymopentin and its immunomodulating effects in Wistar rats Eur. J. Pharm. Sci. 36 572-9
25. Caraher E M, Parenteau M, Gruber H and Scott F W 2000 Flow cytometric analysis of intracellular IFN-, IL-4 and IL-10 in CD3+ 4+ T-cells from rat spleen 244 29-40 J. Immunol. Methods
26. Ozer J S, Chetty R, Kenna G, Palandra J, Zhang Y, Lanevschi A, Koppiker N, Souberbielle B E and Ramaiah S K 2010 Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury Regul. Toxicol. Pharmacol. 56 237-46
27. Caglar K, Kinalp C, Arpaci F, Turan M, Saglam K, Ozturk B, Komurcu Ş, Yavuz İ, Yenicesu M and Ozet A 2002 Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by autologous stem-cell transplantation Nephrol. Dial. Transplant. 17 1931-5 (Pubitemid 35277090)
28. Yang Y, Lan J, Xu Z, Chen T, Zhao T, Cheng T, Shen J, Lv S and Zhang H 2013 Toxicity and biodistribution of aqueous synthesized ZnS and ZnO quantum dots in mice Nanotoxicology 8 107-16
29. Singh-Joy S D and McLain V C 2008 Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate as used in cosmetics Int. J. Toxicol. 27 93
30. Akhgari M, Abdollahi M, Kebryaeezadeh A, Hosseini R and Sabzevari O 2003 Biochemical evidence for free radical-induced lipid peroxidation as a mechanism for subchronic toxicity of malathion in blood and liver of rats Hum. Exp. Toxicol. 22 205-11 (Pubitemid 36582596)
31. de Visser K E, Eichten A and Coussens L M 2006 Paradoxical roles of the immune system during cancer development Nat. Rev. Cancer 6 24-37 (Pubitemid 43053650)
32. Son H-Y, Lee S, Park S-B, Kim M-S, Choi E-J, Singh T S, Bae Y, Kwack S J, Kang T S and Shin H-I 2010 Toxic effects of mercuric sulfide on immune organs in mice Immunopharmacol. Immunotoxicol. 32 277-83
33. Cesta M F 2006 Normal structure, function, and histology of the spleen Toxicol. Pathol. 34 455-65 (Pubitemid 44652213)
34. Pearse G 2006 Normal structure, function and histology of the thymus Toxicol. Pathol. 34 504-14 (Pubitemid 44652215)
35. Huyan X H, Lin Y P, Gao T, Chen R Y and Fan Y M 2011 Immunosuppressive effect of cyclophosphamide on white blood cells and lymphocyte subpopulations from peripheral blood of Balb/c mice Int. Immunopharmacol. 11 1293-7
36. Schroeder H W Jr and Cavacini L 2010 Structure and function of immunoglobulins J. Allergy Clin. Immunol. 125 S41-52
37. Yin Y, Chen D, Qiao M, Lu Z and Hu H 2006 Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin J. Control. Release 116 337-45 (Pubitemid 44827411)
38. Kim J J, Simbiri K A, Sin J I, Dang K, Oh J, Dentchev T, Lee D, Nottingham L K, Chalian A A and Mccallus D 1999 Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV J. Interferon Cytokine Res. 19 77-84 (Pubitemid 29070235)
39. Webster R, Elliott V, Park B K, Walker D, Hankin M and Taupin P 2009 PEGylated Protein Drugs: Basic Science and Clinical Applications (Berlin: Springer) 127-46
40. Fadeel B and Garcia-Bennett A E 2010 Better safe than sorry: understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications Adv. Drug. Deliv. Rev. 62 362-74
41. Sayes C M, Reed K L and Warheit D B 2007 Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles Toxicol. Sci. 97 163-80 (Pubitemid 47072165)
42. Lee S, Yun H S and Kim S H 2011 The comparative effects of mesoporous silica nanoparticles and colloidal silica on inflammation and apoptosis Biomaterials 32 9434-43
43. Lee S, Kim M S, Lee D, Kwon T K, Khang D, Yun H S and Kim S H 2013 The comparative immunotoxicity of mesoporous silica nanoparticles and colloidal silica nanoparticles in mice Int. J. Nanomedicine 8 147-58